From January to may 2016, the Russian pharmaceutical manufacturers shipped from the warehouses of medicines to RUB 121.8 billion, estimated by the consulting company RNC Pharma based on data of Rosstat. This is 40.7% higher than in the first five months of last year. The sum takes into account both commercial and public segments (the drugs procured by the health Ministry in government auctions). In 2015, shipments of Russian products have grown by about 25%, estimates the Director of development RNC Pharma Nikolay Bespalov.
Positive dynamics Bespalov binds to several factors: first, the Russian medicines appeared on the market in 2014 and 2015, have been replaced by imported ones, such as “Imatinib” and “Glatiramer acetate” (potent anti-leukemic and immunomodulatory drugs. — RBC) ; secondly, Russian customers to save actively switch to Russian drugs due to their lower cost. 2015 Russian drugs rose by 20%, and for the first five months of this 5-7%, but they still tend to be cheaper than imported counterparts, says Bespalov.
“Import substitution occurs. In the current economic situation people are looking for opportunities to optimize your budget, including for drugs,” agrees the first Vice-President of the company ROSTRA Alexander Tarasov.
The representative of a pharmaceutical distributor “SIA international” confirmed that the share of Russian producers in total volume of purchases increased, albeit not so high. This was due to the increase in both selling prices and sales volumes. Positive dynamics can be attributed to the increase in the share of public procurement that involves a representative from a major pharmaceutical manufacturer.
In December 2015, Prime Minister Dmitry Medvedev signed a decree about the limitation of foreign procurement of medicines included in the list of vital and essential drugs (EDL). According to the document imported drugs were denied the right to participate in the auction, if there are proposals from at least two domestic suppliers. The market of public procurement of essential drugs is estimated at nearly 200 billion rubles.
The pharmaceutical manufacturer BIOCAD CEO Dmitry Morozov told RBC that his company demonstrates unprecedented growth: sales from January to may of 2016, compared to the same period last year increased by 69%. “In real terms the growth is slightly more modest than in cash, but this is due to the release of new high-value products — “Trastuzumab and Bevacizumab,” — says Morozov. The main part of the business SUPPLIES is allocated to the public segment.
The commercial segment of the market in ruble terms decreased over the first four months of 2016 8.3%, estimated by experts DSM Group. In natural units, the market capacity in April 2016, amounted 327,9 million packages, which is 4.5% lower than a year earlier.